Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Rheumatology (Oxford) · 2010 · PMC2806066 · PMID 19447770

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There was a trend towards a decrease in all three endothelium activation/injury markers and ET-1 serum levels in the RTX group at 24 weeks, compared with baseline, which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.